MET Tyrosine Kinase Inhibitor SGX523

Regulatory

Approvals (0)

Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.

Data not yet available

No regulatory approval recorded. Absence here is not evidence of absence: only ingested jurisdictions are covered.

What CancerIndex knows

Curated evidence below
Sources

Derived

Development pipeline

Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.

Scope	Stage	Max phase	Active	Recruiting	Phase 3	Trials	Approvals	Jurisdictions	First approval	First trial
All cancers	Phase1	Phase 1	0	0	0	2	0	—	—	2008-01

Computedclinicaltrialsci-drug-pipeline-v1Stage rules

Data updated 16 hours agoSource updated unknown

Curated evidence

Clinical evidence (1)

CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.

civicCuratedShowing 1–1 of 1 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
HGF EXPRESSION1
MET Tyrosine Kinase Inhibitor SGX523

Clinical trials

Trials with this intervention (2)

Most recently updated first, 50 per page.

clinicaltrialsPublishedShowing 1–2 of 2 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT00606879	Safety Study of SGX523, a Small Molecule Met Inhibitor, to Treat Solid Tumors	terminated	Phase 1	46	SGX Pharmaceuticals, Inc.INDUSTRY	1	Jul 24, 2008	clinicaltrials
NCT00607399	Safety Study of SGX523, a Small Molecule Met Inhibitor, to Treat Solid Tumors	terminated	Phase 1	46